ProShare Advisors
XFOR icon

ProShare Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

ProShare Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.4K Buy
+10,588
New +$43.4K ﹤0.01% 1846
2025
Q2 		– Sell
-1,231
Closed -$8.73K – 2197
2025
Q1 		$8.73K Sell
1,231
-347
-22% -$4.78K ﹤0.01% 2071
2024
Q4 		$34.7K Sell
1,578
-539
-25% -$8.59K ﹤0.01% 2226
2024
Q3 		$42.5K Buy
2,117
+1,558
+279% +$32.5K ﹤0.01% 1993
2024
Q2 		$9.73K Sell
559
-191
-25% -$6.25K ﹤0.01% 1836
2024
Q1 		$31.3K Buy
750
+71
+10% +$1.98K ﹤0.01% 1953
2023
Q4 		$17.1K Buy
679
+146
+27% +$3.55K ﹤0.01% 1924
2023
Q3 		$17.4K Sell
533
-1
-0.2% -$44 ﹤0.01% 1794
2023
Q2 		$31.1K Buy
+534
New +$27.4K ﹤0.01% 1812

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ProShare Advisors's XFOR Position: Q2 2026 in Review

ProShare Advisors opened a new position in X4 Pharmaceuticals (XFOR) in Q2 2026: 10,588 shares worth $49.4K. The stake represents ﹤0.01% of the portfolio and ranks #1846 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in XFOR as recently as Q1 2025.

ProShare Advisors first reported a position in XFOR in Q2 2023 and has held it in 9 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • ProShare Advisors held 10,588 shares of X4 Pharmaceuticals worth $49.4K as of Q2 2026.
  • X4 Pharmaceuticals was a new ProShare Advisors position in Q2 2026.
  • X4 Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1846 holding.
  • ProShare Advisors first reported a position in X4 Pharmaceuticals in Q2 2023 and has held it in 9 quarters since.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.